Short Interest in Heart Test Laboratories, Inc. (NASDAQ:HSCS) Declines By 13.5%

Heart Test Laboratories, Inc. (NASDAQ:HSCS) saw a significant decrease in short interest in January. As of January 31st, there was short interest totalling 33,300 shares, a decrease of 13.5% from the January 15th total of 38,500 shares. Based on an average daily trading volume, of 35,000 shares, the short-interest ratio is currently 1.0 days. Approximately 4.1% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

Separately, Maxim Group reissued a “buy” rating and issued a $12.00 price target on shares of Heart Test Laboratories in a research note on Wednesday, December 18th.

Heart Test Laboratories Stock Performance

Shares of NASDAQ HSCS traded up $0.10 on Friday, reaching $3.91. 19,626 shares of the company’s stock traded hands, compared to its average volume of 17,597. Heart Test Laboratories has a 12 month low of $2.36 and a 12 month high of $18.50. The business’s 50 day simple moving average is $3.62 and its two-hundred day simple moving average is $3.44. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.72 and a quick ratio of 1.52.

Heart Test Laboratories (NASDAQ:HSCS) last announced its earnings results on Monday, December 16th. The company reported ($2.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.30) by $0.03. During the same quarter in the prior year, the company posted ($15.92) EPS. Equities analysts predict that Heart Test Laboratories will post -10.01 EPS for the current year.

About Heart Test Laboratories

Heart Test Laboratories, Inc, a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals.